Ovid Therapeutics (NASDAQ:OVID) Earning Somewhat Critical Press Coverage, Study Shows

Media headlines about Ovid Therapeutics (NASDAQ:OVID) have trended somewhat negative on Friday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ovid Therapeutics earned a news sentiment score of -0.05 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.0704884973412 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the news headlines that may have impacted Accern Sentiment Analysis’s scoring:

How to Become a New Pot Stock Millionaire

NASDAQ:OVID opened at $8.21 on Friday. The company has a market cap of $154.60 and a price-to-earnings ratio of -2.04. Ovid Therapeutics has a fifty-two week low of $5.28 and a fifty-two week high of $15.93.

Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings results on Thursday, March 29th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). equities research analysts forecast that Ovid Therapeutics will post -2.11 earnings per share for the current fiscal year.

Several research firms have recently issued reports on OVID. Zacks Investment Research downgraded Ovid Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday. ValuEngine raised Ovid Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday. Cowen reissued a “buy” rating on shares of Ovid Therapeutics in a research report on Sunday, April 1st. Finally, Piper Jaffray initiated coverage on shares of Ovid Therapeutics in a research report on Friday, March 9th. They set an “overweight” rating and a $20.00 target price for the company. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $19.50.

WARNING: This piece of content was reported by BBNS and is the property of of BBNS. If you are reading this piece of content on another domain, it was copied illegally and republished in violation of international trademark & copyright laws. The correct version of this piece of content can be accessed at https://baseballnewssource.com/2018/04/06/somewhat-negative-press-coverage-somewhat-unlikely-to-impact-ovid-therapeutics-ovid-share-price/2029452.html.

Ovid Therapeutics Company Profile

Ovid Therapeutics Inc, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate that is in Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome, as well as in preclinical development stage for pediatrics with angelman syndrome.

Insider Buying and Selling by Quarter for Ovid Therapeutics (NASDAQ:OVID)

Receive News & Ratings for Ovid Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Bryce Harper Hits 406-Foot Home Run While Breaking His Bat
Rick Porcello’s Strong Start Gives Boost to Red Sox
Rick Porcello’s Strong Start Gives Boost to Red Sox
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Two Bench Clearing Incidents Revive Red Sox-Yankees Rivalry
Xander Bogaerts Goes on Red Sox DL
Xander Bogaerts Goes on Red Sox DL
Ohtani Goes Deep in Third Straight Game for Angels
Ohtani Goes Deep in Third Straight Game for Angels
Charlie Blackmon Agrees to Contract Extension with Colorado Rockies
Charlie Blackmon Agrees to Contract Extension with Colorado Rockies


Leave a Reply

 
© 2006-2018 BBNS.